| SC 13G/A | 2024-02-14 | Empyrean Capital Partners, LP | AEON Biopharma, Inc. | 0 | 0.0% | EDGAR |
| SC 13G | 2024-02-14 | Polar Asset Management Partners Inc. | AEON Biopharma, Inc. | 3,675,000 | 9.9% | EDGAR |
| SC 13D/A | 2023-08-22 | Strathspey Crown Holdings Group, LLC | AEON Biopharma, Inc. | 2,031,773 | - | EDGAR |
| SC 13D | 2023-07-31 | Strathspey Crown Holdings Group, LLC | AEON Biopharma, Inc. | 9,420,370 | - | EDGAR |
| SC 13G | 2023-07-31 | Atalaya Capital Management LP | AEON Biopharma, Inc. | 3,675,000 | 9.9% | EDGAR |
| SC 13D | 2023-07-28 | Daewoong Co., Ltd | AEON Biopharma, Inc. | 6,577,604 | 24.0% | EDGAR |
| SC 13G/A | 2023-07-20 | Saba Capital Management, L.P. | Priveterra Acquisition Corp. | - | 0.0% | EDGAR |
| SC 13G/A | 2023-06-12 | GLAZER CAPITAL, LLC | Priveterra Acquisition Corp. | 59,166 | 3.0% | EDGAR |
| SC 13G | 2023-03-10 | GLAZER CAPITAL, LLC | Priveterra Acquisition Corp. | 227,544 | 11.4% | EDGAR |
| SC 13G | 2021-02-22 | Empyrean Capital Partners, LP | Priveterra Acquisition Corp. | 1,400,000 | 5.1% | EDGAR |